Paget disease of bone

Trends in Endocrinology and Metabolism

Volumn 19, Issue 7, 2008, Pages 246-253

  Cundy, Tim ^a   Bolland, Mark ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; ETIDRONIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; ZOLEDRONIC ACID;

BENIGN TUMOR; BONE TURNOVER; CLINICAL FEATURE; CLINICAL TRIAL; CYTOLOGY; DISEASE SEVERITY; ENVIRONMENTAL FACTOR; GENE MUTATION; GENETIC SUSCEPTIBILITY; HEREDITY; HISTOPATHOLOGY; HUMAN; PAGET BONE DISEASE; PREVALENCE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

HUMANS; NEOPLASMS; OSTEITIS DEFORMANS;

EID: 49649114546     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2008.06.001     Document Type: Review

References (53)

1. Wells C., and Woodhouse N.J.Y. Paget's disease in an Anglo-Saxon. Med. Hist. 19 (1975) 396-400
2. Schmorl G. Über osteitis deformans Paget. Virchows Arch. 283 (1932) 694-751
3. Barker D.J.P. The epidemiology of Paget's disease of bone. Br. Med. Bull. 40 (1984) 396-400
4. Reasbeck J.C., et al. Radiological prevalence of Paget's disease in Dunedin, New Zealand. Br. Med. J. (Clin. Res. Ed.) 286 (1983) 1937
5. Griz L., et al. Paget's disease of bone. Arq. Bras. Endocrinol. Metab. 50 (2006) 814-822
6. Barker D.J.P., et al. Paget's disease of bone: the Lancashire focus. BMJ 280 (1980) 1105-1107
7. Gennari L., et al. Paget's disease of bone in Italy. J. Bone Miner. Res. 21 (2006) P14-21
8. Lopez-Abente G., et al. Identification of possible areas of high prevalence of Paget's disease of bone in Spain. Clin. Exp. Rheumatol. 21 (2003) 635-638
9. Cooper C., et al. The epidemiology of Paget's disease in Britain: is the prevalence decreasing?. J. Bone Miner. Res. 14 (1999) 192-197
10. Doyle T., et al. Paget's disease in New Zealand: evidence for declining prevalence. Bone 31 (2002) 616-619
11. Poór G., et al. Epidemiology of Paget's disease in Europe: the prevalence is decreasing. J. Bone Miner. Res. 21 (2006) 1545-1549
12. Gardner M.J., and Barker D.J.P. Mortality from malignant tumours of bone and Paget's disease in the United States, and England and Wales. Int. J. Epidemiol. 7 (1978) 121-130
13. Cundy T., et al. Evidence for secular change in Paget's disease. Bone 20 (1997) 69-71
14. Cundy H.R., et al. Paget's disease of bone in New Zealand: continued decline in disease severity. Calcif. Tissue Int. 75 (2004) 358-364
15. Kanis J.A. Pathophysiology and Treatment of Paget's Disease of Bone (1991), Martin Dunitz
16. Menaa C., et al. 1,25-dihdroxyvitamin D3 sensitivity of osteoclast precursors from patients with Paget's disease. J. Bone. Miner. Res. 15 (2000) 228-236
17. 3 and RANKL. Bone 27 (2000) 409-416
18. Menaa C., et al. Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget's disease of bone. J. Clin. Invest. 105 (2000) 1833-1838
19. II-17, a VDR-binding protein, in the increased osteoclast formation in Paget's disease of bone. J. Bone Miner. Res. 19 (2004) 1154-1164
20. Nagy Z.B., et al. Gene expression profiling in Paget's disease of bone: up-regulation of interferon signalling pathways in pagetic monocytes and lymphocytes. J. Bone Miner. Res. 23 (2008) 253-259
21. Layfield R. The molecular pathogenesis of Paget disease of bone. Expert Rev. Mol. Med. 9 (2007) 1-13
22. Laurin N., et al. Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am. J. Hum. Genet. 70 (2002) 1582-1588
23. Hocking L.J., et al. Domain specific mutations in sequestosome 1 (SQSTM1) cause familial and sporadic Paget's disease. Hum. Mol. Genet. 11 (2002) 2735-2739
24. Morissette J., et al. Sequestosome 1: mutation frequencies, haplotypes and phenotypes in familial Paget's disease of bone. J. Bone Miner. Res. 21 supp 2 (2006) P38-P44
25. Lucas G.J.A., et al. Ubiquitin-associated domain mutations of SQSTM1 in Paget's disease of bone: evidence for a founder effect in patients of British descent. J. Bone Miner. Res. 20 (2005) 227-231
26. Hocking L.J., et al. UBA domain mutations of SQSTM1 in Paget's disease of bone: genotype-phenotype correlation, functional analysis and structural consequences. J. Bone Miner. Res. 19 (2004) 1122-1127
27. Bolland M.J., et al. Delayed development of Paget's disease in offspring inheriting SQSTM1 mutations. J. Bone Miner. Res. 22 (2007) 411-415
28. Kurihara N., et al. Mutation of the sequestosome 1 (p62) gene increases osteoclastogenesis but does not induce Paget disease. J. Clin. Invest. 117 (2007) 133-142
29. Lucas G.J.A., et al. Evidence for an important susceptibility gene for Paget disease on chromosome 10p13 in families without SQSTM1 mutations. J. Bone Miner. Res. 23 (2008) 58-63
30. Mills B.G., and Singer F.R. Nuclear inclusions in Paget's disease of bone. Science 194 (1976) 201-202
31. Reddy S.V., et al. Measles virus nucleocapsid transcript expression is not Restricted to the osteoclast lineage in patients with Paget's disease of bone. Exp. Hematol. 27 (1999) 1528-1532
32. Friedrichs W.E., et al. Sequence analysis of measles virus nucleocapsid transcripts in patients with Paget's disease. J. Bone Miner. Res. 17 (2002) 145-151
33. Mee A.P., et al. Detection of canine distemper virus in 100% of Paget's disease samples by in situ-reverse transcriptase polymerase chain reaction. Bone 23 (1998) 171-175
34. O'Driscoll J.B., and Anderson D.C. Past pets and Paget's disease. Lancet 2 (1985) 919-921
35. Kurihara N., et al. Osteoclasts expressing the measles virus nucleocapsid gene display a pagetic phenotype. J. Clin. Invest. 105 (2000) 607-614
36. Selby P.L., et al. Canine distemper virus induces human osteoclastogenesis through NF-κB and sequestosome 1/p62 activation. J. Bone Miner. Res. 21 (2006) 1750-1756
37. Helfrich M.H., et al. A negative search for a paramyxoviral etiology of Paget's disease of bone: molecular, immunological, and ultrastructural studies in UK patients. J. Bone Miner. Res. 15 (2000) 2315-2329
38. Ralston S.H., et al. Multicenter blinded analysis of RT-PCR detection methods for paramyxoviruses in relation to Paget's disease of bone. J. Bone Miner. Res. 22 (2007) 569-577
39. Matthews, B.G. et al. Failure to detect measles virus RNA in bone cells from patients with Paget's disease. J. Clin. Endocrinol. Metab. (in press)
40. Lever J.H. Paget's disease of bone in Lancashire and arsenic pesticide in cotton mill wastewater: a speculative hypothesis. Bone 31 (2002) 434-436
41. Aono J., et al. Activation of Nrf2 and accumulation of ubiquinated A170 by arsenic in osteoblasts. Biochem. Biophys. Res. Commun. 305 (2003) 271-277
42. Daroszewska A., and Ralston S.H. Mechanisms of disease: genetics of Paget's disease of bone and related disorders. Nat. Clin. Pract. Rheumatol. 2 (2006) 270-277
43. Siris E.S., et al. Medical management of Paget's disease of bone: indications for treatment and review of current therapies. J. Bone Miner. Res. 21 supp 2 (2006) P94-P98
44. Reid I.R., et al. Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: a randomized, placebo-controlled trial. Am. J. Med. 101 (1996) 341-348
45. Reid I.R., et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N. Engl. J. Med. 353 (2005) 898-908
46. Douglas D.L., et al. Paget's disease: improvement of spinal cord dysfunction with diphosphonates and calcitonin. Metab. Bone. Dis. Relat. Res. 3 (1981) 327-336
47. Van Staa T.P., et al. Incidence and natural history of Paget's disease of bone in England and Wales. J. Bone Miner. Res. 17 (2002) 465-471
48. Langston A.L., et al. Clinical determinants of quality of life in Paget's disease of bone. Calcif. Tissue Int. 80 (2007) 1-9
49. Naot D., et al. Differential gene expression in cultured osteoblasts and bone marrow stromal cells from patients with Paget's disease of bone. J. Bone Miner. Res. 22 (2007) 298-309
50. Ishimi Y., et al. Il-6 is produced by osteoblasts and induces bone resorption. J. Immunol. 145 (1990) 3297-3303
51. Roodman G.D., et al. Interleukin 6. A potential autocrine/paracrine factor in Paget's disease of bone. J. Clin. Invest. 89 (1992) 46-52
52. Frenzen C.L., and Murray D. A cell kinetics justification for Gompertz' equation. SIAM J. Appl. Math. 46 (1986) 614-629
53. Nellissery M.J., et al. Evidence for a novel osteosarcoma tumor-suppressor gene in the chromosome 18 region genetically linked with Paget disease of bone. Am. J. Hum. Genet. 63 (1998) 817-824